Value of monitoring activated clotting time when Bivalirudin is used as the sole anticoagulation agent for percutaneous coronary intervention

被引：24

作者：

Cheneau, E ^{[1
]}

Canos, D ^{[1
]}

Kuchulakanti, PK ^{[1
]}

Rha, SW ^{[1
]}

Satler, LF ^{[1
]}

Suddath, WO ^{[1
]}

Kent, KM ^{[1
]}

Pichard, AD ^{[1
]}

Waksman, R ^{[1
]}

机构：

[1] Washington Hosp Ctr, Washington, DC 20010 USA

来源：

AMERICAN JOURNAL OF CARDIOLOGY | 2004年 / 94卷 / 06期

关键词：

D O I：

10.1016/j.amjcard.2004.05.068

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Anticoagulation during percutaneous coronary intervention (PCI) requires the monitoring of activated clotting. time (ACT) to protect from periprocedural ischemic and bleeding complications; however, the optimal ACT values have not been established when PCI is performed with bivalirudin. After 495 consecutive patients treated for coronary artery disease with PCI received bivaliruclin as a single anticoagulation agent, it was found that ACT is reproducible when bivaliruclin is used during PCI and does not correlate with clinical events. (C) 2004 by Excerpta Medica, Inc.

引用

收藏

页码：789 / 792

页数：4

相关论文

共 10 条

[1] TREATMENT WITH BIVALIRUDIN (HIRULOG) AS COMPARED WITH HEPARIN DURING CORONARY ANGIOPLASTY FOR UNSTABLE OR POSTINFARCTION ANGINA [J].

BITTL, JA ;

STRONY, J ;

BRINKER, JA ;

AHMED, WH ;

MECKEL, CR ;

CHAITMAN, BR ;

MARAGANORE, J ;

DEUTSCH, E ;

ADELMAN, B .

NEW ENGLAND JOURNAL OF MEDICINE, 1995, 333 (12) :764-769

[2]

Chew DP, 2001, CIRCULATION, V103, P961

[3] RELATION BETWEEN PROCEDURAL ACTIVATED COAGULATION TIME AND OUTCOME AFTER PERCUTANEOUS TRANSLUMINAL CORONARY ANGIOPLASTY [J].

FERGUSON, JJ ;

DOUGHERTY, KG ;

GAOS, CM ;

BUSH, HS ;

MARSH, KC ;

LEACHMAN, DR .

JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 1994, 23 (05) :1061-1065

[4] NONOPERATIVE DILATATION OF CORONARY-ARTERY STENOSIS - PERCUTANEOUS TRANS-LUMINAL CORONARY ANGIOPLASTY [J].

GRUNTZIG, AR ;

SENNING, A ;

SIEGENTHALER, WE .

NEW ENGLAND JOURNAL OF MEDICINE, 1979, 301 (02) :61-68

[5] Relationship between activated clotting time during percutaneous intervention and subsequent bleeding complications [J].

Hillegass, WB ;

Brott, BC ;

Chapman, GD ;

Phillips, HR ;

Stack, RS ;

Tcheng, JE ;

Califf, RM .

AMERICAN HEART JOURNAL, 2002, 144 (03) :501-507

[6] Bivalirudin and provisional glycoprotein IIb/IIIa blockade compared with heparin and planned glycoprotein IIb/IIIa blockade during percutaneous coronary intervention - REPLACE-2 Randomized Trial [J].

Lincoff, AM ;

Bittl, JA ;

Harrington, RA ;

Feit, F ;

Kleiman, NS ;

Jackman, JD ;

Sarembock, IJ ;

Cohen, DJ ;

Spriggs, D ;

Ebrahimi, R ;

Keren, G ;

Carr, J ;

Cohen, EA ;

Betriu, A ;

Desmet, W ;

Kereiakes, DJ ;

Rutsch, W ;

Wilcox, RG ;

de Feyter, PJ ;

Vahanian, A ;

Topol, EJ .

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2003, 289 (07) :853-863

[7] Relation between activated clotting time during angioplasty and abrupt closure [J].

Narins, CR ;

Hillegass, WB ;

Nelson, CL ;

Tcheng, JE ;

Harrington, RA ;

Phillips, HR ;

Stack, RS ;

Califf, RM .

CIRCULATION, 1996, 93 (04) :667-671

[8] Effectiveness of heparin in preventing thrombin generation and thrombin activity in patients undergoing coronary intervention [J].

Ragosta, M ;

Karve, M ;

Brezynski, D ;

Humphries, J ;

Sanders, JM ;

Sarembock, IJ ;

Gimple, LW ;

Powers, ER .

AMERICAN HEART JOURNAL, 1999, 137 (02) :250-257

[9]

RATH B, 1990, BRIT HEART J, V63, P18

[10] Relationship between heparin anticoagulation and clinical outcomes in coronary stent intervention - Observations from the ESPRIT trial [J].

Tolleson, TR ;

O'Shea, JC ;

Bittl, JA ;

Hillegass, WB ;

Williams, KA ;

Levine, G ;

Harrington, RA ;

Tcheng, JE .

JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2003, 41 (03) :386-393